AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19377380
Drug: Hyaluronan-based heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with low-systemic heparin (125 IU/kg, ACT >250 s)
Trial: 19377380
Drug: Hyaluronan-based heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with full dose heparin
Trial: 9653434
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies for prevention and treatment of MAS
Trial: 2273080
Drug: Guanfacine 1
RxNorm normalized name: guanfacine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine 1 mg every night
Trial: 2273080
Drug: Prazosin 1
RxNorm normalized name: prazosin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 1 mg three times a day
Trial: 6269789
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ranitidine intravenously
Trial: 6269789
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg cimetidine intravenously
Trial: 17530471
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg daily titrated every 3 months for 18 months)
Trial: 6145832
Drug: Tamoxifen and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen and/or subsequent endocrine therapy
Trial: 31211607
Drug: Hypnotherapy (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotherapy (weekly session for 1 month, total of four sessions)
Trial: 28969439
Drug: CCBT (computer-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCBT (computer-assisted cognitive-behavioral therapy) using the 'Good Days Ahead' program
Trial: 26481083
Drug: candesartan/hydrochlorothiazide 16/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan/hydrochlorothiazide 16/12.5 mg/d
Trial: 30893638
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 600 mg/kg diet/day
Trial: 30893638
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 1200 mg/kg diet/day
Trial: 30893638
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 1800 mg/kg diet/day
Trial: 30893638
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 0 mg/kg diet/day (Control)
Trial: 24293455
Drug: Fingolimod 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 1.25 mg daily
Trial: 24293455
Drug: Fingolimod 5
RxNorm normalized name: fingolimod 500 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 5 mg daily
Trial: 17464718
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg day(-1)) for 7 days
Trial: 15163892
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of both therapies
Trial: 11683695
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg simplified lansoprazole suspension (nasogastrically)
Trial: 11683695
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg intravenous pantoprazole
Trial: 9712471
Drug: 25‐mg ephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐mg ephedrine capsule
Trial: 3167527
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and systemic antibiotics (Group C)
Trial: 31788791
Drug: Fast propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast propofol infusion
Trial: 31788791
Drug: Slow propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slow propofol infusion
Trial: 20043136
Drug: DBDS-MPH (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBDS-MPH (40 mg)
Trial: 2141512
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (vincristine during irradiation and maintenance CCNU and vincristine, given in 6-weekly cycles for 1 year)
Trial: 16097225
Drug: Chin cup
RxNorm normalized name: CHIN-UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chin cup therapy with 600 g of force applied in 13 patients
Trial: 9882760
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg p.o.)
Trial: 10445787
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of MET dose from 375 mg (in groups B and C) to 750 mg/day (in group A)
Trial: 25470746
Drug: Doravirine (6-1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (6-1,200 mg)
Trial: 25470746
Drug: Doravirine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (120 mg) coadministered with midazolam
Trial: 25470746
Drug: Doravirine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (up to 1,200 mg single doses and up to 750 mg multiple doses)
Trial: 15909262
Drug: Azithromycin at
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin at 60 mg/kg per course
Trial: 15909262
Drug: Azithromycin at
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin at 30 mg/kg per course
Trial: 15909262
Drug: Three-day regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day regimens of azithromycin (500 mg/day) in adults
Trial: 15909262
Drug: 10-day comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day comparator antibiotics
Trial: 24729507
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice daily for 7 days
Trial: 2676266
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment with chlorthalidone and atenolol (or reserpine)
Trial: 31185327
Drug: Post-mastectomy intensity
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-mastectomy intensity modulated proton therapy (IMPT)
Trial: 23322466
Drug: Tocilizumab-MTX 4
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tocilizumab-MTX 4 mg/kg
Trial: 19364000
Drug: morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.1 mg
Trial: 19364000
Drug: morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.2 mg
Trial: 3064599
Drug: Furosemide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (50 mg)
Trial: 31229329
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide skin preparation
Trial: 28930903
Drug: Localized cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Localized cold therapy
Trial: 25578927
Drug: 22 g
RxNorm normalized name: Empty Carpuject 2 mL 22 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 g freeze‐dried blueberry powder
Trial: 22775199
Drug: Insulin euglycaemic
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin euglycaemic clamp
Trial: 3071588
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg three times a day)
Trial: 24705975
Drug: Pazopanib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (600 mg)
Trial: 24159785
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus thermoheliox (group 1)
Trial: 18787899
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 microg once daily for 7 days)
Trial: 16169256
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1000 mg/day to 3000 mg/day as adjunctive therapy
Trial: 15124554
Drug: Partial breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial breast irradiation (intraoperative radiotherapy, brachytherapy, or external radiotherapy using 3D conformal radiation therapy)
Trial: 24231837
Drug: Oxybutynin vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin vaginal ring 4 mg daily
Trial: 10702886
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg
Trial: 19958962
Drug: Intravenous allogeneic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous allogeneic human mesenchymal stem cells (hMSCs)
Trial: 31917835
Drug: Somapacitan 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somapacitan 0.04 mg/kg/wk
Trial: 31917835
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH 0.034 mg/kg/d
Trial: 31917835
Drug: Somapacitan 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somapacitan 0.08 mg/kg/wk
Trial: 22306585
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose plus booster on day 21
Trial: 12195350
Drug: Adjunctive therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapeutic vaccine trial (for 11 of the 16 subjects)
Trial: 12195350
Drug: Discontinued therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued therapy
Trial: 24153411
Drug: 2-week taper
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week taper
Trial: 24153411
Drug: 1-week taper
RxNorm normalized name: CAPER BERRY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week taper
Trial: 18290565
Drug: Basiliximab induction
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab induction therapy combined with Calcineurin inhibitors (CNI) and steroids
Trial: 7739947
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg orally 1 hour before imaging procedure
Trial: 2287655
Drug: Individual supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual supportive treatment plus brief counseling contacts
Trial: 7255511
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (1.2 g)
Trial: 30151994
Drug: PPI- AS
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI- AS group (esomeprazole 20-mg bid, rabeprazole 10-mg bid, or lansoprazole 30-mg bid; amoxicillin 750-mg bid; sitafloxacin 100-mg bid for 7 days)
Trial: 7663659
Drug: rhDNase once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhDNase once daily
Trial: 29987605
Drug: Breast-Conserving Therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-Conserving Therapy (BCT)
Trial: 20850556
Drug: Cortisol (2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (2mg IV infusion)
Trial: 20850556
Drug: Placebo (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (IV infusion)
Trial: 16445306
Drug: Rivastigmine 3-12
RxNorm normalized name: rivastigmine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 3-12 mg/day
Trial: 10337433
Drug: Ketorolac ophthalmic
RxNorm normalized name: ketorolac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac ophthalmic solution (0.5%)
Trial: 2180748
Drug: Methylprednisolone (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (low dose)
Trial: 24689367
Drug: Conventional hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional hormone replacement cycle without prostaglandin
Trial: 21176144
Drug: Alternative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapy (drotrecogin alfa at 24/30/36 μg/kg/hr for 48 to 168 hours)
Trial: 21176144
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (drotrecogin alfa at 24 μg/kg/hr infusion for 96 hours)
Trial: 18255347
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with stent placement
Trial: 16182683
Drug: Controlled sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled sleep restriction with hypnotic administration in the first week
Trial: 12634619
Drug: TLC D‐99
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC D‐99 (60 mg/m2) with cyclophosphamide (600 mg/m2)
Trial: 12634619
Drug: Conventional doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doxorubicin (60 mg/m2) with cyclophosphamide (600 mg/m2)
Trial: 8879472
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ondansetron, p.o.
Trial: 1947853
Drug: Oral alphacalcidol
RxNorm normalized name: alfacalcidol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alphacalcidol (1 microgram daily) for 6 months
Trial: 1947853
Drug: Intravenous alphacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alphacalcidol for 4 months
Trial: 22908151
Drug: Omadacycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omadacycline (100 mg i.v. QD, option to transition to 200 mg orally QD)
Trial: 22908151
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg i.v. BID, option to transition to 600 mg orally BID)
Trial: 20004445
Drug: Restricted intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted intravenous fluid regimen adjusted by serum lactate level (group A)
Trial: 20004445
Drug: Restricted intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted intravenous fluid regimen (group R)
Trial: 16828477
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg daily for 21 days)
Trial: 16828477
Drug: Estrogen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (2 mg daily for 21 days)
Trial: 16828477
Drug: Estrogen+Progestagen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen+Progestagen (2 mg E(2) + 5 mg medroxyprogesterone acetate daily for 21 days)
Trial: 10407221
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormonal treatment)
Trial: 12492794
Drug: Epidural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural block with 15 ml of 0.5% bupivacaine
Trial: 12492794
Drug: Psoas compartment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoas compartment block with 30 ml of 0.5% bupivacaine
Trial: 9745421
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg
Trial: 17568837
Drug: Light polymerization
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light polymerization of both the adhesive and resin cement in G-2
Trial: 17568837
Drug: G-2 (opaque
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-2 (opaque post)
Trial: 17568837
Drug: Autopolymerized adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autopolymerized adhesive in G-4
Trial: 11158015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormone treatment)
Trial: 10023313
Drug: High-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiotherapy (59.4 Gy in 6.5 weeks)
Trial: 26422874
Drug: lidocaine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 1.0 mg/kg
Trial: 19924605
Drug: Low-dose pioglitazone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pioglitazone (15 mg/day)
Trial: 15297687
Drug: Wheat grass
RxNorm normalized name: Wheat grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat grass juice (100 mL daily)
Trial: 3540874
Drug: Amfenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amfenac 100 mg
Trial: 10552992
Drug: Sequential antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential antimicrobial therapy (SAT)
Trial: 1757612
Drug: 0.05% halobetasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% halobetasol ointment
Trial: 6184729
Drug: Sulprostone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulprostone (500 micrograms administered i.m. every four or six hours)
Trial: 31736082
Drug: Stepped-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care treatment starting with 14 weekly sessions of manualized CBT
Trial: 12045127
Drug: Control: Twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Twice-weekly rifampin plus isoniazid (not explicitly detailed in the abstract)
Trial: 601870
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with isoniazid and rifampicin
Trial: 601870
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with isoniazid and ethambutol
Trial: 601870
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment progress
Trial: 7215718
Drug: Carbenoxolone 150
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone 150 mg/day for 6 months
Trial: 31585702
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation medication prescription recommended by counselor
Trial: 31585702
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of inpatient smoking cessation medication
Trial: 21142446
Drug: HAART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART treatment interruption (TI)
Trial: 7581094
Drug: rhIL-6 therapy
RxNorm normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIL-6 therapy at 0.3 microgram/kg/day
Trial: 7581094
Drug: rhIL-6 therapy
RxNorm normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIL-6 therapy at 1 microgram/kg/day
Trial: 7581094
Drug: rhIL-6 therapy
RxNorm normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIL-6 therapy at 3 micrograms/kg/day
Trial: 7581094
Drug: rhIL-6 therapy
RxNorm normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIL-6 therapy (all doses)
Trial: 7581094
Drug: Maximal tolerated
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal tolerated dose of rhIL-6
Trial: 2179979
Drug: High-dose piracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose piracetam (24 g per day)
Trial: 2179979
Drug: Low-dose piracetam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose piracetam (6 g per day)
Trial: 30650479
Drug: Shenmai Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai Injection (SI), 50 mL each time, once per day for 10 days
Trial: 30650479
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional drugs for CHD)
Trial: 21450987
Drug: Liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.2 mg
Trial: 15358033
Drug: NCX‐4016 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX‐4016 800 mg twice a day
Trial: 15358033
Drug: NCX‐4016 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX‐4016 800 mg twice a day plus aspirin 325 mg
Trial: 28352985
Drug: Cabozantinib 100
RxNorm normalized name: cabozantinib 100 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 100 mg qd
Trial: 28352985
Drug: Cabozantinib 100
RxNorm normalized name: cabozantinib 100 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 100 mg qd and Erlotinib 50 mg qd
Trial: 28352985
Drug: Cabozantinib 100
RxNorm normalized name: cabozantinib 100 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 100 mg qd and Erlotinib 50 mg qd (phase I MTD)
Trial: 20441725
Drug: Imaginal exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaginal exposure therapy (3 to 5 sessions)